☆ 4.7 Meeting Abstract

Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors

JOURNAL OF CLINICAL ONCOLOGY (2019)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 37, Issue 4, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2019.37.4_suppl.99

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

James J. Harding, Melinda Telli, Pamela Munster, Martin H. Voss, Jeffrey R. Infante, Angela DeMichele, Mark Dunphy, Mai H. Le, Chris Molineaux, Keith Orford, Frank Parlati, Sam H. Whiting, Mark K. Bennett, Nizar M. Tannir, Funda Meric-Bernstam

Summary: The oral first-in-class glutaminase inhibitor telaglenastat was found to be safe with a favorable PK/PD profile and showed promise of antitumor activity in treatment-refractory solid tumor patients. Expansion cohorts demonstrated a disease control rate of 43% with a defined recommended phase II dose of 800 mg twice-daily. These results support further clinical development of telaglenastat.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors

Hui-Jen Tsai, Her-Shyong Shiah, Jang-Yang Chang, Wu-Chou Su, Nai-Jung Chiang, Li-Tzong Chen

Summary: This study determined the maximal tolerated dose (MTD) of S-1 when combined with sorafenib for refractory solid tumors to be 30 mg/m(2) bid. Some patients achieved durable partial response or stable disease with this regimen. Further phase II studies are warranted to evaluate the efficacy of this combination in advanced pNET and colon cancer.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients

Jianming Xu, Jiuwei Cui, Haiping Jiang, Yan Zeng, Xiuyu Cong

Summary: This study determined the MTD, RP2D, pharmacokinetics, safety, and preliminary efficacy of EVER4010001 plus pembrolizumab in patients with advanced solid tumors. The results showed that 80 mg BID was the MTD and RP2D for EVER4010001 plus pembrolizumab.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors

Bo Gao, Mark Voskoboynik, Adam Cooper, Kate Wilkinson, Siao Hoon, Chih-Yi Hsieh, Suixiong Cai, Ye Edward Tian, Jun Bao, Ning Ma, Chen Wang, Ming Zhang, Baoyue Li, Mingchuan Guo, Ruiyu Zhou, Xiaozhu Wang, Cong Xu, Paul de Souza

Summary: This study evaluated the safety and preliminary efficacy of senaparib in patients with advanced solid tumors. The results showed that senaparib was well tolerated in Australian patients and exhibited encouraging antitumor activity. The recommended phase 2 dose for senaparib was determined to be 100 mg daily.

CANCER (2023)

Add to Collection

Article Oncology

Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors

Her-Shyong Shiah, Nai-Jung Chiang, Chia-Chi Lin, Chia-Jui Yen, Hui-Jen Tsai, Shang-Yin Wu, Wu-Chou Su, Kwang-Yu Chang, Ching-Chiung Wang, Jang-Yang Chang, Li-Tzong Chen

Summary: The novel microtubule inhibitor SCB01A has vascular disrupting activity and is safe and tolerable in patients with solid tumors, with a maximum tolerated dose of 24 mg/m(2) every 21 days and a half-life of approximately 2.5 hours. Treatment-related adverse events included anemia, nausea, vomiting, and some patients experienced neurotoxicity.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors

Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan

Summary: This study evaluated the efficacy and tolerability of avelumab in Chinese patients. The results showed that avelumab at different doses can stabilize the disease and have partial responses in some patients' tumors.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Oncology

Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors

Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan

Summary: This study evaluated the safety and pharmacokinetics of avelumab in Chinese patients with advanced solid tumors. The results were consistent with previous global studies, showing some therapeutic effects in Chinese patients.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Oncology

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors

Amita Patnaik, Erika Hamilton, Yan Xing, Drew W. Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, Ai-Min Hui

Summary: This study examines the safety and antitumor efficacy of a novel CDK4/6 inhibitor, FCN-437c, in patients with advanced solid tumors. The results show promising signs of durable tumor response and disease control. Further research is needed to investigate the safety and efficacy of FCN-437c.

CANCERS (2022)

Add to Collection

Article Oncology

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas

Andrew L. Coveler, David C. Smith, Tycel Phillips, Brendan D. Curti, Sanjay Goel, Amitkumar N. Mehta, Timothy M. Kuzel, Svetomir N. Markovic, Olivier Rixe, David L. Bajor, Thomas F. Gajewski, Martin Gutierrez, Hun Ju Lee, Ajay K. Gopal, Paolo Caimi, Elisabeth Heath, John A. Thompson, Sahar Ansari, Celine Jacquemont, Ariel Topletz-Erickson, Peigen Zhou, Michael W. Schmitt, Juneko E. Grilley-Olson

Summary: SEA-CD40, an investigational antibody that activates CD40, demonstrated tolerability and potent immune activation in patients with solid tumors and lymphoma, showing evidence of antitumor activity. Further evaluation of SEA-CD40 as a component of combination therapy is warranted.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Oncology

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors

Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, Takuya Suzuki, Takao Takase, Reiko Nagai, Kohei Yamaguchi, Taro Semba, Zi-Ming Zhao, Min Ren, Noboru Yamamoto

Summary: This study reports the dose-escalation part of a phase I study of liposomal eribulin in Japanese patients with advanced solid tumors. The study found that liposomal eribulin was well tolerated at a dosage of 2.0 mg/m(2) once every three weeks and 1.5 mg/m(2) once every two weeks, and recommended a dosage of 2.0 mg/m(2) once every three weeks.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Immunology

A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors

James J. Harding, Ignacio Garrido-Laguna, Xiaoying Chen, Cynthia Basu, Afshin Dowlati, Alison Forgie, Andrea T. Hooper, Cris Kamperschroer, Steven I. Max, Allison Moreau, Megan Shannon, Gilbert Y. Wong, David S. Hong

Summary: P-cadherin is overexpressed in solid tumors, and PF-06671008 shows antitumor activity by engaging P-cadherin and CD3 epsilon. This phase 1 study evaluates the safety and tolerability of PF-06671008 and provides insights into managing immune-related adverse events. Limited antitumor activity and cytokine release syndrome were observed.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors

Yuxiang Ma, Wenfeng Fang, Hongyun Zhao, Sai Praneeth Bathena, Amol Tendolkar, Jennifer Sheng, Li Zhang

Summary: The study found that the overall safety profiles of ipilimumab in Chinese patients with solid tumors were consistent with previous U.S. studies, with lower systemic exposures in Chinese patients but overlapping serum concentrations between Chinese and U.S. populations. The drug was well tolerated in Chinese patients, without new safety concerns.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors

Apostolia Maria Tsimberidou, Claire F. Verschraegen, Robert Wesolowski, Chi-Sheng Shia, Pei Hsu, Tillman E. Pearce

Summary: This is a report of a phase 1 dose-escalation study of OBI-3424 monotherapy in patients with advanced solid tumors. The study used a classic 3 + 3 design to determine the maximum tolerated dose and recommended phase 2 dose of OBI-3424. The results showed that OBI-3424 was well tolerated, with dose-limiting hematologic toxicities observed at the 12 mg/m(2) dose.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Dionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, Mateus Crespo, Ana Ferreira, Bora Gurel, Toby Prout, Malaka Ameratunga, Maxime Chenard-Poirier, Andra Curcean, Claudia Bertan, Chloe Baker, Susana Miranda, Nahal Masrour, Wentin Chen, Rita Pereira, Ines Figueiredo, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Ruth Riisnaes, Mona Parmar, Alison Turner, Suzanne Carreira, Christina Yap, Robert Brown, Nina Tunariu, Udai Banerji, Juanita Lopez, Johann de Bono, Anna Minchom

Summary: The combination of guadecitabine and pembrolizumab improves tumor sensitivity to immune checkpoint inhibitors and reverses previous resistance. This study demonstrates the safety and tolerability of the treatment regimen and observes some anticancer activity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors

Elena Garralda, Alison M. Schram, Philippe L. Bedard, Gary K. Schwartz, Eunice Yuen, Samuel C. McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaojian Xu, Patricia LoRusso

Summary: LY3405105 is a promising CDK7 inhibitor with good bioavailability and selectivity. However, the clinical trial showed limited efficacy and no plans for further development. The MTD of LY3405105 monotherapy was determined to be 20 mg QD.

ONCOLOGIST (2023)

Add to Collection

Article Oncology

Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)

Masahito Kotaka, Shigeyoshi Iwamoto, Hironaga Satake, Daisuke Sakai, Toshihiro Kudo, Mutsumi Fukunaga, Ken Konishi, Yoshihito Ide, Taro Ikumoto, Akihito Tsuji, Yasushi Sano, Takeshi Kato, Naotoshi Sugimoto, Taroh Satoh, Akiyoshi Kanazawa, Takayasu Kurata, Takeharu Yamanaka, Naohiro Tomita

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Convolutional Neural Network Can Recognize Drug Resistance of Single Cancer Cells

Kiminori Yanagisawa, Masayasu Toratani, Ayumu Asai, Masamitsu Konno, Hirohiko Niioka, Tsunekazu Mizushima, Taroh Satoh, Jun Miyake, Kazuhiko Ogawa, Andrea Vecchione, Yuichiro Doki, Hidetoshi Eguchi, Hideshi Ishii

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Oncology

Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)

Yukinori Kurokawa, Jin Matsuyama, Kazuhiro Nishikawa, Atsushi Takeno, Yutaka Kimura, Kazumasa Fujitani, Ryohei Kawabata, Yoichi Makari, Tetsuji Terazawa, Hisato Kawakami, Daisuke Sakai, Toshio Shimokawa, Taroh Satoh

Summary: In this study comparing the efficacy and toxicities of docetaxel plus S-1 (DS) and cisplatin plus S-1 (CS) regimens for AGC without measurable lesions, DS showed slightly but non-significantly less toxicity and higher efficacy in terms of overall survival compared to CS.

GASTRIC CANCER (2021)

Add to Collection

Article Surgery

Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma

Yoko Hiraki, Yutaka Kimura, Motohiro Imano, Hiroaki Kato, Mitsuru Iwama, Osamu Shiraishi, Atsushi Yasuda, Masayuki Shinkai, Tomoki Makino, Masaaki Motoori, Makoto Yamasaki, Hiroshi Miyata, Takao Satou, Taroh Satoh, Hiroshi Furukawa, Masahiko Yano, Yuichiro Doki, Takushi Yasuda

Summary: The study aimed to determine the clinical significance of micrometastases after neoadjuvant chemotherapy and the difference in controlling micrometastases using different regimens in resectable advanced esophageal squamous cell carcinoma. The results indicated that controlling micrometastases in the lymph nodes varied by regimen and may be associated with preventing ESCC recurrence.

SURGERY TODAY (2021)

Add to Collection

Article Oncology

Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib

Yasushi Murachi, Daisuke Sakai, Jun Koseki, Chiaki Inagaki, Naohiro Nishida, Toshifumi Yamaguchi, Taroh Satoh

Summary: This study retrospectively reviewed the medical records of patients treated with regorafenib between 2013 and 2019, finding that sarcopenia is a significant negative predictor for overall survival in these patients. Patients receiving a total regorafenib dose of < 3360 mg or a relative dose intensity of less than 75% also experienced shorter survival times.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

PhaseIIStudy of Panitumumab Monotherapy inChemotherapy-NaiveFrail or Elderly Patients with UnresectableRAS Wild-TypeColorectal Cancer:OGSG1602

Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Katsuya Ohta, Shingo Noura, Hironaga Satake, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh

Summary: Lessons learned from this study indicate that panitumumab monotherapy is effective and feasible for frail or elderly patients with RAS wild-type unresectable colorectal cancer, especially for left-sided tumors. It could be considered as an additional therapeutic option for those who are not suitable for intensive chemotherapy.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, Shu-Kui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, Eric van Cutsem, Maria Alsina, Zhu Alexander Cao, Jia Lu, Pooja Bhagia, Chie-Schin Shih, Yelena Y. Janjigian

Summary: Current treatment options for patients with HER2-positive advanced gastric cancer are limited, with poor prognosis. Pembrolizumab in combination with trastuzumab and chemotherapy may provide a benefit for these patients.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Oncology

Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital

Chiaki Inagaki, Daichi Maeda, Kazue Hatake, Yuki Sato, Kae Hashimoto, Daisuke Sakai, Shinichi Yachida, Norio Nonomura, Taroh Satoh

Summary: Next-generation sequencing (NGS) assay is widely utilized in clinical practice in Japan due to its reimbursement by the country's universal health-care system for cancer patients who have completed standard treatment. However, reimbursement is limited to a specific patient population, making it challenging for some patients to benefit from the NGS assay results. Early performance of NGS assay and broader reimbursement are necessary to maximize the clinical benefit and delivery of precision oncology. Access to clinical trials and disclosure of presumed germline findings can also impact patient outcomes.

CANCERS (2021)

Add to Collection

Article Oncology

Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer

Ryohei Yukimoto, Naohiro Nishida, Tsuyoshi Hata, Shiki Fujino, Takayuki Ogino, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Taroh Satoh, Yamamoto Hirofumi, Tsunekazu Mizushima, Yuichiro Doki, Hidetoshi Eguchi

Summary: The study identified a unique metabolic gene profile in BRAF V600E-mutated tumors, with high expression of enolase 2 (ENO2) and enhanced dependency on it. Knockdown of ENO2 inhibited proliferation and migration of cancer cells, and increased sensitivity to BRAF V600E inhibitor. Inhibition of ENO2 also suppressed MAPK and PI3K/Akt signaling pathways, suggesting an additional oncogenic role of ENO2 in CRC progression.

CANCER SCIENCE (2021)

Add to Collection

Article Oncology

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, Hideaki Bando, Hisateru Yasui, Taito Esaki, Tetsuji Terazawa, Taroh Satoh, Eiji Shinozaki, Tomohiro Nishina, Yu Sunakawa, Yoshito Komatsu, Hiroki Hara, Eiji Oki, Nobuhisa Matsuhashi, Takashi Ohta, Takeshi Kato, Koushiro Ohtsubo, Takeshi Kawakami, Naohiro Okano, Yoshiyuki Yamamoto, Takanobu Yamada, Akihito Tsuji, Justin Odegaard, Hiroya Taniguchi, Toshihiko Doi, Satoshi Fujii, Takayuki Yoshino

Summary: ctDNA sequencing is more effective in detecting FGFR2 amplification in patients with advanced gastric cancer compared to tissue analysis, and these patients may respond to FGFR inhibitors.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Pancreatic Cancer Research beyond DNA Mutations

Hiromichi Sato, Kazuki Sasaki, Tomoaki Hara, Yoshiko Tsuji, Yasuko Arao, Chihiro Otsuka, Yumiko Hamano, Mirei Ogita, Shogo Kobayashi, Eric di Luccio, Takaaki Hirotsu, Yuichiro Doki, Hidetoshi Eguchi, Taroh Satoh, Shizuka Uchida, Hideshi Ishii

Summary: This article describes the causes and complexity of pancreatic ductal adenocarcinoma (PDAC), emphasizing the importance of early diagnosis and the multifaceted characteristics of PDAC in terms of cancer cell metabolism, mesenchymal cells, and metagenomics. The article also mentions various pathway alterations associated with PDAC treatment refractoriness and prospects for the application of new technologies.

BIOMOLECULES (2022)

Add to Collection

Article Oncology

Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

Hisato Kawakami, Kazuhiro Nishikawa, Toshio Shimokawa, Kazumasa Fujitani, Shigeyuki Tamura, Shunji Endo, Michiya Kobayashi, Junji Kawada, Yukinori Kurokawa, Akira Tsuburaya, Takaki Yoshikawa, Junichi Sakamoto, Taroh Satoh

Summary: There is no clear preference between S-1 and capecitabine in combination with platinum agent as first-line therapy for patients with HER2-negative unresectable advanced or recurrent gastric cancer. However, S-1 plus cisplatin (SP) achieves deeper tumor shrinkage than capecitabine plus cisplatin (XP) in differentiated gastric cancer, leading to longer overall survival. In undifferentiated gastric cancer, SP consistently showed better clinical results than XP.

CANCERS (2022)

Add to Collection

Article Oncology

Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer

Hideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, Manabu Shiozawa, Hisateru Yasui, Taito Esaki, Yoshinori Kagawa, Tadamichi Denda, Taroh Satoh, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, Masahiro Goto, Satoshi Yuki, Tomohiro Nishina, Eiji Oki, Eiji Shinozaki, Nobuhisa Matsuhashi, Naoki Takahashi, Akihito Tsuji, Koushiro Ohtsubo, Masashi Wakabayashi, Takashi Ikeno, Masayuki Hata, Justin Odegaard, Takayuki Yoshino

Summary: The relationship between metastatic site and ctDNA detection was investigated in patients with limited-extent metastatic colorectal cancer (mCRC). The results showed that the metastatic site had an impact on ctDNA detection.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Oncology

Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): a multi-institutional retrospective study

Toshifumi Yamaguchi, Atsuo Takashima, Kengo Nagashima, Masanori Terashima, Masaki Aizawa, Manabu Ohashi, Ryo Tanaka, Tatsuya Yamada, Takahiro Kinoshita, Hisayuki Matsushita, Koshiro Ishiyama, Kei Hosoda, Yasuhiro Yuasa, Shusuke Haruta, Naoki Kakihara, Kazuhiro Nishikawa, Gen Yunome, Taroh Satoh, Takeo Fukagawa, Hitoshi Katai, Narikazu Boku

Summary: This study investigated the efficacy of preoperative chemotherapy as initial treatment in GC patients with CY1 and/or P1a. Results showed that preoperative chemotherapy did not provide a survival benefit for GC patients with CY1 and/or P1a, but showed favorable survival in patients who converted to P0 and CY0.

GASTRIC CANCER (2021)

Add to Collection

Meeting Abstract Oncology

Identification of cancer hallmarks associated with benefit in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade

Emon Elboudwarej, Carrie Brachmann, Daniel V. T. Catenacci, David Cunningham, Eric Van Cutsem, Richard D. Kennedy, Shauna Lambe, Gemma E. Logan, Jean Philippe Metges, Kei Muro, Taroh Satoh, Atsuo Takashima, Zev A. Wainberg, Steven M. Walker, Kensei Yamaguchi, Marianna Zavodovskaya, Scott D. Patterson, Pankaj Bhargava, Narikazu Boku, Manish A. Shah

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.